China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
China Pharma Holdings, Inc. (NYSE American: CPHI) has announced plans to launch its Dry Eye Disease Therapeutic Device in China by Q1 2025. The device, developed by its subsidiary Hainan Helpson Medical and Biotechnology Co., , is a patented medical treatment for dry eye disease. With 400 million dry eye disease patients in China, the market is projected to reach $579.51 million by 2030, growing at a CAGR of 6.04% from 2023-2030.
The device uses ophthalmic oxygen-enriched atomization technology to spray tiny oxygen-rich droplets into the eyes, improving moisture, oxygen supply, and tear fluid quality. This physical therapy approach aims to avoid drug-related side effects while providing more direct and comfortable treatment.
China Pharma Holdings, Inc. (NYSE American: CPHI) ha annunciato piani per lanciare il suo Dispositivo Terapeutico per la Malattia dell'Occhio Secco in Cina entro il primo trimestre del 2025. Il dispositivo, sviluppato dalla sua filiale Hainan Helpson Medical and Biotechnology Co., è un trattamento medico brevettato per la malattia dell'occhio secco. Con 400 milioni di pazienti affetti da occhio secco in Cina, il mercato è previsto raggiungere 579,51 milioni di dollari entro il 2030, crescendo a un tasso di crescita annuale composto (CAGR) del 6,04% dal 2023 al 2030.
Il dispositivo utilizza una tecnologia di atomizzazione arricchita di ossigeno oftalmico per spruzzare minuscole gocce di ossigeno negli occhi, migliorando l'umidità, l'apporto di ossigeno e la qualità del fluido lacrimale. Questo approccio di terapia fisica mira a evitare effetti collaterali legati ai farmaci, fornendo un trattamento più diretto e confortevole.
China Pharma Holdings, Inc. (NYSE American: CPHI) ha anunciado planes para lanzar su Dispositivo Terapéutico para la Enfermedad del Ojo Seco en China para el primer trimestre de 2025. El dispositivo, desarrollado por su filial Hainan Helpson Medical and Biotechnology Co., es un tratamiento médico patentado para la enfermedad del ojo seco. Con 400 millones de pacientes con enfermedad del ojo seco en China, se proyecta que el mercado alcance 579.51 millones de dólares para 2030, creciendo a una tasa compuesta anual (CAGR) del 6.04% de 2023 a 2030.
El dispositivo utiliza una tecnología de atomización enriquecida con oxígeno oftálmico para pulverizar pequeñas gotas ricas en oxígeno en los ojos, mejorando la humedad, el suministro de oxígeno y la calidad del líquido lagrimal. Este enfoque de terapia física tiene como objetivo evitar efectos secundarios relacionados con medicamentos, proporcionado un tratamiento más directo y cómodo.
China Pharma Holdings, Inc. (NYSE American: CPHI)는 2025년 1분기까지 중국에서 건조안 증상 치료 장치를 출시할 계획을 발표했습니다. 이 장치는 자회사인 Hainan Helpson Medical and Biotechnology Co.에 의해 개발된 건조안 증상에 대한 특허 의학 치료 장비입니다. 중국에는 4억 명의 건조안 증상 환자가 있어, 시장 규모는 2030년까지 5억 7951만 달러에 이를 것으로 예상되며, 2023년부터 2030년까지 연평균 성장률(CAGR)은 6.04%에 이를 것으로 보입니다.
이 장치는 안과용 산소가 풍부한 미세 분사 기술을 사용하여 눈에 산소가 풍부한 미세한 방울을 뿌려 습도, 산소 공급 및 눈물의 질을 개선합니다. 이 물리 치료 접근법은 약물 관련 부작용을 피하면서 보다 직접적이고 편안한 치료를 제공하는 것을 목표로 합니다.
China Pharma Holdings, Inc. (NYSE American: CPHI) a annoncé des plans pour lancer son Dispositif Thérapeutique pour la Maladie de l'Œil Sec en Chine d'ici le premier trimestre 2025. Le dispositif, développé par sa filiale Hainan Helpson Medical and Biotechnology Co., est un traitement médical breveté pour la maladie de l'œil sec. Avec 400 millions de patients souffrant de sécheresse oculaire en Chine, le marché devrait atteindre 579,51 millions de dollars d'ici 2030, avec un taux de croissance annuel composé (CAGR) de 6,04 % entre 2023 et 2030.
Le dispositif utilise une technologie d'atomisation enrichie en oxygène ophtalmique pour pulvériser de minuscules gouttes riches en oxygène dans les yeux, améliorant l'humidité, l'apport en oxygène et la qualité des larmes. Cette approche de thérapie physique vise à éviter les effets secondaires liés aux médicaments tout en offrant un traitement plus direct et plus confortable.
China Pharma Holdings, Inc. (NYSE American: CPHI) hat Pläne angekündigt, sein Therapeutisches Gerät gegen Trockenes Auge bis zum ersten Quartal 2025 in China einzuführen. Das Gerät, das von der Tochtergesellschaft Hainan Helpson Medical and Biotechnology Co. entwickelt wurde, ist eine patentierte medizinische Behandlung für das trockene Auge. Mit 400 Millionen Patienten mit trockenem Auge in China, wird erwartet, dass der Markt bis 2030 einen Wert von 579,51 Millionen Dollar erreicht, bei einer jährlichen Wachstumsrate (CAGR) von 6,04% zwischen 2023 und 2030.
Das Gerät verwendet ophthalmologische, sauerstoffangereicherte Verneblungstechnologie, um winzige sauerstoffreiche Tröpfchen in die Augen zu sprühen, was die Feuchtigkeit, die Sauerstoffversorgung und die Qualität der Tränenflüssigkeit verbessert. Dieser physikalische Therapieansatz zielt darauf ab, medikamentenbezogene Nebenwirkungen zu vermeiden und gleichzeitig eine direktere und angenehmere Behandlung zu bieten.
- Launch of patented Dry Eye Disease Therapeutic Device expected in Q1 2025
- Large market potential with 400 million dry eye disease patients in China
- Chinese dry eye disease market projected to reach $579.51 million by 2030
- Innovative technology using oxygen-enriched atomization for treatment
- None.
Insights
The announcement of China Pharma's Dry Eye Disease Therapeutic Device launch is promising but faces challenges. The device's oxygen-rich atomization technology offers a novel approach, potentially addressing limitations of current treatments. However, market penetration may be challenging due to established competitors and the need for clinical validation.
The Q1 2025 launch timeline seems ambitious, considering regulatory hurdles in China's medical device market. The company must ensure robust clinical data and regulatory compliance to avoid delays. The
Investors should monitor progress on regulatory approvals, clinical trials and partnership developments in the coming months to gauge the device's potential success.
The dry eye disease market in China presents a substantial opportunity for China Pharma. With an estimated 400 million patients and a projected CAGR of
However, market education and adoption could be significant hurdles. The success of the device will largely depend on:
- Effectiveness compared to existing treatments
- Pricing strategy and reimbursement policies
- Distribution channels and partnerships with eye care professionals
China Pharma's ability to execute on these fronts will be important for capturing a meaningful share of this growing market.
- It is a medical treatment device for dry eye disease under patent protection;
- The Company, through Helpson, acquired the technology at the end of 2022 and has subsequently carried out the corresponding commercialization, as well as the registration and application process of the product;
- It has completed production commissioning and third-party testing by now.
In
Treatments for dry eye-related indications include two forms of secretagogues, oral and topical, which are widely recommended for first-line and second-line treatments. A major factor driving the segment's growth includes the awareness campaigns regarding dry eye diseases by vision science and optometry. Our device is embedded with an ophthalmic oxygen enriched atomization therapeutic instrument.
Using such technology, our device can spray tiny oxygen-rich droplets evenly into patient's eyes, thereby increasing the moisture and oxygen supply of the eye surface and improving the quality and stability of the tear fluid. This type of physical therapy avoids the side effects that may be brought about by drugs, and can also effect more directly on the eyes, improving the effectiveness and comfort of the treatment.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc--expects-to-launch-its-dry-eye-disease-therapeutic-device-in-the-first-quarter-of-2025-302225097.html
SOURCE China Pharma Holdings, Inc.
FAQ
When will China Pharma Holdings (CPHI) launch its Dry Eye Disease Therapeutic Device?
What is the market size for dry eye disease in China?
How does China Pharma's (CPHI) Dry Eye Disease Therapeutic Device work?
What is the prevalence of dry eye disease in China?
